Topics covered:
• The FDA approvals for targeted agents in bladder cancer
• The role of NGS and IHC testing in treatment planning
• The evolving landscape of perioperative therapies and clinical trials
• Strategies for sequencing treatments in patients with advanced bladder cancer
Recorded live at the ASCO-GU conference, this episode dived deep into the latest advancements in bladder cancer treatment, including the incorporation of NGS testing and the significance of targeted therapies like Erdafitinib and HER2 IHC testing. Dr. Nizam shared her expertise on navigating the complexities of bladder cancer management and the importance of real-world evidence in clinical practice.